Eli Lilly and Company ($LLY) — Equity Initiation Report
As of 2026-06-18
Company Snapshot / Key Financial Metrics (FY2025–Q1 2026)
| Metric | Q1 2026 | FY2025 | FY2024 | YoY Change (FY25 vs FY24) |
|---|---|---|---|---|
| Revenue ($M) | 19,799 | 65,179 | 45,043 | +45% |
| Net Income – Reported ($M) | 7,396 | 20,640 | 10,590 | +95% |
| EPS – Reported ($) | 8.26 | 22.95 | 11.71 | +96% |
| Net Income – Non-GAAP ($M) | 7,663 | 21,768 | 11,747 | +85% |
| EPS – Non-GAAP ($) | 8.55 | 24.21 | 12.99 | +86% |
| Gross Margin (%) | 81.9 | 83.0 | 81.3 | +1.7pp |
| Gross Margin – Non-GAAP (%) | 82.6 | 83.8 | 82.5 | +1.3pp |
| R&D Expense ($M) | 3,510 | 13,337 | 10,991 | +21% |
| Marketing, Selling & Admin ($M) | 2,934 | 11,094 | 8,594 | +29% |
| Operating Income ($M) | 8,915 | 26,302 | 12,899 | +104% |
| Operating Margin (%)* | 45.0 | 40.3 | 28.6 | +11.7pp |
| Effective Tax Rate (%) | 16.4 | 19.8 | 16.5 | +3.3pp |
| Dividends Paid per Share ($) | 1.73 | 6.00 | 5.20 | +15% |
| Share Repurchases ($M) | 2,400 | 1,500 |
*Operating margin calculated as Operating Income / Revenue.
Segment/Revenue Breakdown by Key Product (Q1 2026)
| Product | Q1 2026 Revenue ($M) | Q1 2025 Revenue ($M) | YoY Growth (%) |
|---|---|---|---|
| Mounjaro | 8,662 | 3,842 | +125% |
| Zepbound | 4,160 | 2,312 | +80% |
| Jaypirca | 165 | 92 | +79% |
| Ebglyss | 145 | 60 | +141% |
| Kisunla | 124 | 22 | NM |
| Omvoh | 80 | 37 | +115% |
| Inluriyo | 35 | NM | |
| Total Revenue | 19,799 | 12,729 | +56% |
NM = Not meaningful (product not launched or negligible base).
Key Growth Drivers / Investment Thesis
| Driver / Thesis Element | Details |
|---|---|
| Incretin/GLP-1 Portfolio Leadership | Mounjaro and Zepbound delivered $8.7B and $4.2B in Q1 2026, up +125% and +80% YoY, respectively. |
| Oral GLP-1 Launch (Foundayo) | FDA approval and U.S. launch in Q2 2026; >20,000 patients treated in first weeks; global filings ongoing. |
| International Expansion | Mounjaro launched in 55+ countries; OUS revenue up 81% YoY in Q1 2026; 75% of OUS Mounjaro is out-of-pocket. |
| Pipeline Depth & Diversification | 42 active Phase III programs; new launches in immunology (Ebglyss), oncology (Jaypirca, Inluriyo), neuroscience (Kisunla). |
| Manufacturing Scale | >$55B committed since 2020; capacity doubled YoY; enables rapid volume growth and global launches. |
| Capital Allocation Discipline | R&D up +28% YoY in Q1 2026; $1.5B dividends and $2.4B buybacks in Q1 2026. |
Bull Case vs Bear Case
| Bull Case | Bear Case |
|---|---|
| Sustained double-digit revenue and EPS growth driven by incretin portfolio (Mounjaro, Zepbound, Foundayo) and pipeline launches. | Price erosion accelerates (esp. in U.S. and China), compressing margins despite volume growth. |
| International expansion and new indications (obesity, diabetes, comorbidities) drive further market penetration. | Competitive pressure from Novo Nordisk, generics, and new entrants erodes share and pricing power. |
| Robust pipeline delivers new blockbusters (retatrutide, eloralintide, brenipatide, etc.). | Pipeline setbacks or regulatory delays slow future growth. |
| Manufacturing scale and DTC platforms (LillyDirect) create durable moat. | Supply chain or manufacturing disruptions limit ability to meet demand. |
| Medicare/Medicaid and employer coverage expands addressable market. | U.S. regulatory or reimbursement changes limit access or pricing. |
Major Risks
| Risk Category | Description |
|---|---|
| Pricing Pressure | Low to mid-teens price erosion expected in 2026; China NRDL, U.S. MFN, and cash pay channel sensitivity. |
| Competitive Intensity | Novo Nordisk (Wegovy, Ozempic, oral sema), generics (esp. ex-U.S.), and new modalities. |
| Supply Chain / Manufacturing | Rapid volume growth requires flawless execution; any disruption could impact sales. |
| Pipeline Execution | High R&D spend; failure to deliver on late-stage pipeline (retatrutide, eloralintide, etc.) would impact growth. |
| Regulatory / Reimbursement Changes | U.S. and international policy shifts (Medicare, Medicaid, employer opt-ins) could affect access and pricing. |
| Patent Expiry / IP Challenges | Loss of exclusivity for key products (Trulicity, Verzenio, etc.) could pressure legacy revenue. |
Catalysts to Watch
| Catalyst/Event | Timing / Status | Details |
|---|---|---|
| Foundayo (orforglipron) U.S. launch ramp | Q2–Q4 2026 | Early uptake, PBM access, DTC campaign in Q3, Medicare Bridge in July. |
| Foundayo international launches | Late 2026–2027 | Regulatory reviews in 40+ countries; major OUS launches expected. |
| Retatrutide Phase III readouts | H2 2026 | Obesity (TRIUMPH-1), diabetes (TRANSCEND), additional indications. |
| Medicare/Medicaid access expansion | July 2026 (Bridge), 2027 | $50/month co-pay, potential for broad senior population uptake. |
| Employer Connect platform adoption | H2 2026–2027 | Incremental commercial coverage, opt-in rates. |
| Pipeline milestones (eloralintide, brenipatide) | 2026–2027 | Phase III data, new indications, label expansions. |
| Manufacturing site expansions | 2026–2027 | New facilities in U.S., Europe, Puerto Rico, Alabama, etc. |
| Quarterly earnings and guidance updates | Ongoing | Monitor for volume/price trends, margin trajectory, pipeline progress. |
Business Overview and Competitive Positioning
Eli Lilly and Company is a global pharmaceutical leader focused on innovative medicines across four core therapeutic areas: Cardiometabolic Health (notably incretin/GLP-1s), Oncology, Immunology, and Neuroscience. The company’s revenue mix is increasingly dominated by its incretin portfolio—Mounjaro (tirzepatide), Zepbound (tirzepatide for obesity), and the newly launched oral GLP-1, Foundayo (orforglipron). Lilly has established itself as the global leader in the incretin/GLP-1 space, with a robust pipeline and a rapidly expanding international footprint.
Lilly’s competitive moat is built on:
- First-mover advantage and best-in-class efficacy in dual and triple incretin agonists.
- Manufacturing scale: Over $55B invested since 2020, enabling rapid global launches and supply reliability.
- DTC/consumer engagement: LillyDirect platform and telehealth partnerships reduce friction and expand access.
- Pipeline depth: 42 active Phase III programs, including next-generation obesity, diabetes, and comorbidity therapies.
Key competitors include Novo Nordisk (Ozempic, Wegovy, oral semaglutide), Pfizer, Merck, and AbbVie. Lilly’s differentiated position is underpinned by superior efficacy (e.g., tirzepatide vs. semaglutide), breadth of indications, and global reach.
Recent Financial Performance and Key Product Trends
FY2025 revenue was $65.2B (+45% YoY), with Q1 2026 revenue at $19.8B (+56% YoY).
- Mounjaro: $22.97B in FY2025, $8.66B in Q1 2026 (+125% YoY).
- Zepbound: $13.54B in FY2025, $4.16B in Q1 2026 (+80% YoY).
- International expansion: OUS revenue up 81% YoY in Q1 2026, with 75% of OUS Mounjaro sales out-of-pocket (vs. reimbursed).
- Other key launches: Ebglyss (immunology), Jaypirca (oncology), Kisunla (neuroscience), and Inluriyo (oncology) all posted strong double- or triple-digit growth.
Incretin/GLP-1 franchise is the primary growth engine, with volume growth consistently outpacing price erosion. Management notes, “every time we reduce pricing, we see a pretty large expansion” (Q1 2026 call).
Margin trajectory remains robust:
- FY2025 gross margin was 83.0% (non-GAAP 83.8%), with Q1 2026 at 81.9% (non-GAAP 82.6%).
- Operating margin improved to 45.0% in Q1 2026 (from 40.3% in FY2025).
- Non-GAAP performance margin reached 50% in Q1 2026, up 7pp YoY.
Growth Strategy
Pipeline and Indication Expansion
- Foundayo (orforglipron): First oral GLP-1 for obesity, U.S. launch in Q2 2026, filings in 40+ countries, type 2 diabetes submission imminent.
- Retatrutide: Triple agonist (GIP/GLP-1/glucagon), Phase III readouts in obesity and diabetes expected H2 2026.
- Eloralintide: Selective amylin agonist, Phase III underway for obesity, OA knee pain, OSA, and as add-on therapy.
- Brenipatide: GIP/GLP-1 dual agonist, Phase III in major depressive disorder, Phase II in opioid use disorder and schizophrenia.
Manufacturing Capacity Expansion
- Over $55B committed since 2020; new sites in Wisconsin, North Carolina, Puerto Rico, Texas, Virginia, Alabama, and Europe.
- “We exceeded our goal to produce 1.8x the number of incretin doses in the second half of '25 compared to the second half of '24.”
International Expansion
- Mounjaro launched in 55+ countries; OUS revenue up 81% YoY in Q1 2026.
- China NRDL listing for type 2 diabetes; rapid share gains in Brazil, Korea, UK, and other markets.
- Foundayo OUS launches expected late 2026–2027.
Access and Coverage
- Medicare Bridge program: $50/month co-pay for obesity medicines, starting July 2026, extended through 2027.
- Employer Connect: New platform to drive commercial coverage; ~50% employer opt-in currently, with incremental gains expected in 2027.
Margin Trajectory and Capital Allocation
- R&D investment: $13.3B in FY2025 (+21% YoY), $3.5B in Q1 2026 (+28% YoY); 42 active Phase III programs.
- Capex: Significant, but not separately disclosed; implied in $55B+ manufacturing build-out.
- Dividends: $6.00/share in FY2025 (+15% YoY); $1.73/share in Q1 2026.
- Buybacks: $1.5B in FY2025; $2.4B in Q1 2026.
- Performance margin: Non-GAAP performance margin guided to 47–48.5% for FY2026.
Valuation Context vs Peers
| Company | FY2025 Revenue ($B) | FY2025 Revenue Growth | FY2025 Gross Margin | FY2025 Operating Margin | Key Franchise(s) |
|---|---|---|---|---|---|
| Eli Lilly ($LLY) | 65.2 | +45% | 83.0% | 40.3%* | Incretins, Oncology |
| Novo Nordisk | GLP-1 (Ozempic, Wegovy) | ||||
| Pfizer | Vaccines, Oncology | ||||
| Merck | Oncology, Vaccines | ||||
| AbbVie | Immunology, Oncology |
*Operating margin for LLY calculated as Operating Income / Revenue.
Lilly’s revenue growth and margin profile are sector-leading, driven by its dominant incretin franchise and robust pipeline. Novo Nordisk is the closest peer in GLP-1s, but Lilly’s dual/triple agonist and oral pipeline provide differentiation. Other large-cap peers lag in both topline growth and margin expansion.
Key Risks
- Pricing/Regulatory Pressure: “Price is expected to be a drag on growth in the low to mid-teens” (2026 guidance). China NRDL and U.S. MFN agreements have already led to double-digit price reductions, though volume growth has offset this so far.
- Competition: Novo Nordisk’s oral semaglutide, Wegovy, and Ozempic remain formidable. Generics (especially in India) are stimulating market growth but could pressure share/price over time.
- Manufacturing/Supply Constraints: Rapid volume growth requires flawless execution; any disruption could materially impact sales.
- Pipeline Execution: High R&D spend and ambitious pipeline; setbacks in late-stage trials (retatrutide, eloralintide, brenipatide) would impact future growth.
- Patent Expiry/IP: Trulicity, Verzenio, and other legacy products face patent cliffs; pipeline must offset declines.
- Access/Reimbursement: Medicare Bridge is temporary; long-term access depends on successful transition to standard Part D coverage and broader employer opt-ins.
Catalysts to Watch
- Foundayo (orforglipron) U.S. launch ramp: Monitor prescription trends, PBM access, and DTC campaign impact in Q3 2026.
- International launches of Foundayo: Regulatory approvals and launches in 40+ countries (late 2026–2027).
- Retatrutide Phase III data: Obesity and diabetes readouts in H2 2026.
- Medicare/Medicaid and Employer Connect adoption: Uptake rates and impact on addressable market.
- Pipeline milestones: Eloralintide, brenipatide, and new indications for existing incretins.
- Quarterly earnings/guidance updates: Track volume/price dynamics, margin evolution, and pipeline progress.
Sources
- [2026 Q1 ELI LILLY & CO ($LLY) 2026 Q1 Press Release]
- [2026 Q1 Eli Lilly and Company, Q1 2026 Earnings Call, Apr 30, 2026]
- [2025 Q4 ELI LILLY & CO ($LLY) 2025 Q4 Press Release]
- [2025 Q4 Eli Lilly and Company, Q4 2025 Earnings Call, Feb 04, 2026]
- [2025 Q3 ELI LILLY & CO ($LLY) 2025 Q3 Press Release]
- [2025 Q3 Eli Lilly and Company, Q3 2025 Earnings Call, Oct 30, 2025]
- [2025 Q2 ELI LILLY & CO ($LLY) 2025 Q2 Press Release]
- [2025 Q2 Eli Lilly and Company, Q2 2025 Earnings Call, Aug 07, 2025]
Note on Limitations
This report is based solely on information contained in the provided source documents (press releases and earnings call transcripts) for Eli Lilly & Co. through Q1 2026. Figures for peers are not included where not present in the source documents. All forward-looking statements and guidance reflect management’s most recent disclosures and are subject to change. No external or market data beyond the provided context has been used. For a full investment decision, consult additional sources and the latest SEC filings.
